Semaglutide and Cardiovascular Outcomes
N Engl J Med
.
2024 Feb 22;390(8):767.
doi: 10.1056/NEJMc2400414.
Authors
Laura A Campbell
1
,
Alexa V Jenkins
2
,
Christopher D Jackson
3
Affiliations
1
University of Tennessee Health Science Center, Memphis, TN lcampb55@uthsc.edu.
2
Western Governors University of Salt Lake City, Salt Lake City, UT.
3
University of Tennessee Health Science Center, Memphis, TN.
PMID:
38381685
DOI:
10.1056/NEJMc2400414
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides* / therapeutic use
Humans
Obesity
Substances
semaglutide
Glucagon-Like Peptides